


Unitaid Malaria Portfolio

Eastern and Southern Africa National Malaria Programmes and Partners Annual Meeting

Unitaid at a glance

Accelerate the introduction and adoption of key health products in LMICs

+ with conditions for sustainable and equitable access
+ through inclusive partnerships



HIV, TB and Malaria




Women & children's health



Global health emergencies



Unitaid's current malaria portfolio








*Recently closed


~ Call for Proposal open/recently closed - no investment commitments to date

TIPTOP: Transforming IPT for Optimal Pregnancy







 Lead Grantee	Jhpiego
 Grant Period	2017 - 2022
 Grant Value	US\$ 50M
 Project countries	DRC, Madagascar, Mozambique, Nigeria




 Key findings	<ul style="list-style-type: none">• 2.5–5-fold increase in access to the recommended 3+ IPTp doses• Community delivery did not negatively impact access to ANC –ANC access increased in 50% of project districts• C-IPTp widely accepted by its beneficiaries in project areas• Low additional cost to health system for community delivery
---	--

The Plus Project – Perennial Malaria Chemoprevention



 Lead Grantee	Population Services International
 Grant Period	2021 - 2025
 Grant Value	US\$ 35M
 Project countries	Benin, Cameroon, Cote d'Ivoire, Mozambique +DRC, Ghana, Zambia




 **Grant Impact**

Catalyse uptake of enhanced PMC strategies – including additional contacts and 2nd year of life

RTS,S: Malaria vaccine pilot implementation project



 Lead Grantee	World Health Organization
 Grant Period	2017 – 2023
 Grant Value	US\$ 13M
 Project countries	Ghana, Malawi and Kenya








Grant Impact

Evaluate the feasibility of delivering the required four doses of RTS,S in real-life settings

New Nets Project – partnership with The Global Fund




 Lead Grantee	Innovative Vector Control Consortium (IVCC)
 Grant Period	2018-2022
 Grant Value	US\$66M
 Project countries	Benin, Burkina Faso, Rwanda, Mali, Mozambique, Nigeria, Cote d'Ivoire, Liberia, Ghana, DRC, Malawi, Niger, Cameroon, and Burundi




 Grant Impact	<i>Introduce new long-lasting insecticide-treated nets (LLINs) in areas of insecticide resistance</i>
---	---


Advancing Spatial Repellents for Vector-borne Disease Control




 **Lead Grantee** University of Notre Dame

 **Grant Period** 2019 - 2024

 **Grant Value** US\$ 33.7M

 **Project countries** Kenya, Mali, Sri Lanka, Uganda








 **Grant Impact**

Evaluate slow-release repellents that drive mosquitoes from inhabited areas

Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA)



 Lead Grantee	ISGlobal
 Grant Period	2019 - 2024
 Grant Value	US\$ 25M
 Project countries	Tanzania, Kenya








Grant Impact

Develop a new complementary new-class vector control tool, ivermectin (endectocides)

Partnership for Vivax Elimination (PAVE)



	Lead Grantee	Medicines for Malaria Venture
	Grant Period	2021 - 2025
	Grant Value	US\$ 24.9M
	Project countries	Peru, Ethiopia, India, Indonesia, PNG




 **Grant Impact**


*Introduce new screening and treatment tools to support the elimination *p. vivax* malaria*


Medicines for Malaria Venture – Supply Side Grant



 **Lead Grantee** Medicines for Malaria Venture

 **Grant Period** 2017 - 2023

 **Grant Value** US\$ 5.8M












 **Grant Impact**

Overcome barriers to availability, quality and supply of medicines for severe malaria and malaria prevention

Unitaid's Programmatic Priorities New Strategy 2023-2027

Saving and Improving Lives through Unitaid Investments

 HIV & co-infections	 TB	 Malaria	 Women & children's health	 Respond to global health emergencies
Sustain effectiveness of prevention, treatment	Enable TB prevention tools for high-risk groups	Introduce and optimize prevention tools	Improve access to better tools for safe pregnancy, birth for women & newborns	Improve quality of clinical care packages for COVID-19
Optimize and enable scale of AHD packages of care	Accelerate access to new detection tools	Improve access to quality case management		
Drive HCV elimination through testing, prevention	Accelerate adoption of new drugs and regimens			
Increase access to screen & treat for cervical cancer, STIs	 Improve child survival with triage and treatment tools			
 Accelerate access to self-testing and integrated diagnostics			Decentralize testing and treatment for COVID-19	
 Long-acting and new technologies				
 Intellectual property, regulatory and innovative supply models				

Malaria priority 1: Introduce and optimize prevention tools (vector control, chemoprevention, vaccines)

Adoption of new tools and approaches, in the most impactful combinations

Illustrative portfolio of topics & interventions

- **Short-term (current):** optimize delivery of malaria chemoprevention (PMC) and ensure access to quality-assured drugs; evaluate new vector control tools (spatial repellents and ivermectin)
- **Mid-term (2-3 years):** optimize deployment of prevention tools e.g. through at-scale pilots, innovative delivery approaches, and generating evidence to guide policy and prioritization.
- **Long-term (4-5 years):** lay the groundwork for transformational new prevention tools (e.g. genetically modified mosquitos, long-acting technologies and vaccines)

Malaria Programmatic priority 2: Improve access to quality case management

Facilitate introduction of new tools and integrated approaches for high-risk populations

Illustrative portfolio of topics & interventions

- **Short-term (current):** invest in better tools for *Plasmodium vivax* testing and single-dose radical cure; improve integrated childhood illness management through scaling diagnostics for severe disease detection
- **Mid-term (2-3 years):** enable tools and approaches for resistance management; support the introduction and adoption of anaemia diagnostics in the pipeline with subsequent iron treatment, deployed in conjunction with malaria diagnostics and treatment
- **Long-term (4-5 years):** expand equitable access to quality case management (diagnosis and treatment) of malaria at health facilities, in the community, and in the private sector; lay the groundwork to prepare for the market entry of promising treatments



Thank you

Dale Halliday, Technical Officer, Malaria Strategy
hallidayd@unitaid.who.int